Curis Begins Phase 1 Trial of Anti-Tumor Drug

Xconomy Boston — 

Drug developer Curis (NASDAQ:CRIS), of Cambridge, MA, reported today that it has begun a Phase 1 clinical trial of an anti-cancer small molecule, dubbed CUDC-101. The experimental drug is designed to inhibit tumor cell growth and survival, and 18 to 40 patients are expected to enroll in the clinical trial.

By posting a comment, you agree to our terms and conditions.

Comments are closed.